Potential Role of ACE2 in Coronavirus Disease 2019 (COVID-19) Prevention and Management

Overview

Journal J Transl Int Med

Publisher Sciendo

Specialty General Medicine

Date 2020 May 22

PMID 32435607

Citations 79

Authors

Mengyuan Liu

Ting Wang

Yun Zhou

Yutong Zhao

Yan Zhang

Jianping Li

Affiliations

Soon will be listed here.

Abstract

COVID-19 is the current public health threat all over the world. Unfortunately, there is no specific prevention and treatment strategy for this disease. We aim to explore the potential role of angiotensin-converting enzyme 2 (ACE2) in this regard through this literature review. As a crucial enzyme of renin-angiotensin-aldosterone system (RAAS), ACE2 not only mediates the virus entry but also affects the pathophysiological process of virus-induced acute lung injury (ALI), as well as other organs' damage. As interaction of COVID-19 virus spike and ACE2 is essential for virus infection, COVID-19-specific vaccine based on spike protein, small molecule compound interrupting their interaction, human monoclonal antibody based on receptor-binding domain, and recombinant human ACE2 protein (rhuACE2) have aroused the interests of researchers. Meanwhile, ACE2 could catalyze angiotensin II (Ang II) to form angiotensin 1-7 (Ang 1-7), thus alleviates the harmful effect of Ang II and amplifies the protection effect of Ang1-7. ACE inhibitor and angiotensin II receptor blocker (ARB) have been shown to increase the level of expression of ACE2 and could be potential strategies in protecting lungs, heart, and kidneys. ACE2 plays a very important role in the pathogenesis and pathophysiology of COVID-19 infection. Strategies targeting ACE2 and its ligand, COVID-19 virus spike protein, may provide novel method in the prevention and management of novel coronavirus pneumonia.

Citing Articles

Shock prediction with dipeptidyl peptidase-3 and renin (SPiDeR) in hypoxemic patients with COVID-19.

Busse L, Teixeira J, Schaich C, Ten Lohuis C, Nielsen N, Sturek J J Crit Care. 2024; 85:154950.

PMID: 39546997 PMC: 11697573. DOI: 10.1016/j.jcrc.2024.154950.

Molecular mechanisms of thalidomide effectiveness on COVID-19 patients explained: ACE2 is a new ΔNp63α target gene.

Monteonofrio L, Virdia I, Pozzi S, Quadri R, Amendolare A, Marzano F J Mol Med (Berl). 2024; 102(11):1371-1380.

PMID: 39294414 PMC: 11525293. DOI: 10.1007/s00109-024-02485-x.

A non-enhanced CT-based deep learning diagnostic system for COVID-19 infection at high risk among lung cancer patients.

Du T, Sun Y, Wang X, Jiang T, Xu N, Boukhers Z Front Med (Lausanne). 2024; 11:1444708.

PMID: 39188873 PMC: 11345710. DOI: 10.3389/fmed.2024.1444708.

Phenotypic switch of vascular smooth muscle cells in COVID-19: Role of cholesterol, calcium, and phosphate.

Ghanem L, Essayli D, Kotaich J, Al Zein M, Sahebkar A, Eid A J Cell Physiol. 2024; 239(12):e31424.

PMID: 39188012 PMC: 11649971. DOI: 10.1002/jcp.31424.

Quercetin may reduce the risk of developing the symptoms of COVID-19.

Ajami M, Sotoudeheian M, Houshiar-Rad A, Esmaili M, Naeini F, Mohammadi Nasrabadi F Avicenna J Phytomed. 2024; 14(2):189-201.

PMID: 38966631 PMC: 11221767. DOI: 10.22038/AJP.2023.22920.

References

Ware L, Matthay M . The acute respiratory distress syndrome. N Engl J Med. 2000; 342(18):1334-49. DOI: 10.1056/NEJM200005043421806. View

Kassiri Z, Zhong J, Guo D, Basu R, Wang X, Liu P . Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail. 2009; 2(5):446-55. DOI: 10.1161/CIRCHEARTFAILURE.108.840124. View

Wan Y, Shang J, Graham R, Baric R, Li F . Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol. 2020; 94(7). PMC: 7081895. DOI: 10.1128/JVI.00127-20. View

Qin C, Wang J, Wei Q, She M, Marasco W, Jiang H . An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus. J Pathol. 2005; 206(3):251-9. PMC: 7167940. DOI: 10.1002/path.1769. View

Yamamoto K, Ohishi M, Katsuya T, Ito N, Ikushima M, Kaibe M . Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension. 2006; 47(4):718-26. DOI: 10.1161/01.HYP.0000205833.89478.5b. View

Tian X, Li C, Huang A, Xia S, Lu S, Shi Z . Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020; 9(1):382-385. PMC: 7048180. DOI: 10.1080/22221751.2020.1729069. View

Chan J, Yuan S, Kok K, To K, Chu H, Yang J . A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 395(10223):514-523. PMC: 7159286. DOI: 10.1016/S0140-6736(20)30154-9. View

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

Du L, Zhao G, Lin Y, Chan C, He Y, Jiang S . Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. Vaccine. 2008; 26(13):1644-51. PMC: 2600875. DOI: 10.1016/j.vaccine.2008.01.025. View

10.

Raizada M, Ferreira A . ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol. 2007; 50(2):112-9. DOI: 10.1097/FJC.0b013e3180986219. View

11.

Adedeji A, Severson W, Jonsson C, Singh K, Weiss S, Sarafianos S . Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. J Virol. 2013; 87(14):8017-28. PMC: 3700180. DOI: 10.1128/JVI.00998-13. View

12.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

13.

Keidar S, Gamliel-Lazarovich A, Kaplan M, Pavlotzky E, Hamoud S, Hayek T . Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ Res. 2005; 97(9):946-53. DOI: 10.1161/01.RES.0000187500.24964.7A. View

14.

Nakamura K, Koibuchi N, Nishimatsu H, Higashikuni Y, Hirata Y, Kugiyama K . Candesartan ameliorates cardiac dysfunction observed in angiotensin-converting enzyme 2-deficient mice. Hypertens Res. 2008; 31(10):1953-61. DOI: 10.1291/hypres.31.1953. View

15.

Gwathmey T, Alzayadneh E, Pendergrass K, Chappell M . Novel roles of nuclear angiotensin receptors and signaling mechanisms. Am J Physiol Regul Integr Comp Physiol. 2011; 302(5):R518-30. PMC: 3311515. DOI: 10.1152/ajpregu.00525.2011. View

16.

Han D, Penn-Nicholson A, Cho M . Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor. Virology. 2006; 350(1):15-25. PMC: 7111894. DOI: 10.1016/j.virol.2006.01.029. View

17.

Shenoy V, Gjymishka A, Jarajapu Y, Qi Y, Afzal A, Rigatto K . Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am J Respir Crit Care Med. 2013; 187(6):648-57. PMC: 3733435. DOI: 10.1164/rccm.201205-0880OC. View

18.

Zhang X, Yap Y . Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs. Bioorg Med Chem. 2004; 12(10):2517-21. PMC: 7126105. DOI: 10.1016/j.bmc.2004.03.035. View

19.

He Y, Li J, Du L, Yan X, Hu G, Zhou Y . Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. Vaccine. 2006; 24(26):5498-508. PMC: 7115380. DOI: 10.1016/j.vaccine.2006.04.054. View

20.

Chen Z, Zhang L, Qin C, Ba L, Yi C, Zhang F . Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol. 2005; 79(5):2678-88. PMC: 548443. DOI: 10.1128/JVI.79.5.2678-2688.2005. View